{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:13:51Z","timestamp":1790489631982,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T00:00:00Z","timestamp":1528070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sumitomo Dainippon Pharma Co., Ltd"},{"name":"Taisho Toyama Pharmaceutical Co., Ltd"},{"name":"Daiichi Sankyo Co., Ltd"},{"name":"Pfizer Co., Ltd"},{"name":"Astellas, Inc."},{"DOI":"10.13039\/100012781","name":"MSD K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Toyama Chemical Co., Ltd"},{"name":"MIYARISAN Pharmaceutical Co., Ltd"},{"DOI":"10.13039\/501100005612","name":"Shionogi & Co. Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jiac.2018.05.010","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T20:08:09Z","timestamp":1529438889000},"page":"744-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-8767","authenticated-orcid":false,"given":"Hiroshige","family":"Mikamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6200-6163","authenticated-orcid":false,"given":"Kazuhiro","family":"Tateda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kusachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Takesue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Miki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Oizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Gamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Toyoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2018.05.010_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005665","article-title":"Multi-institution case-control and cohort study of risk factors for the development and mortality of Clostridium difficile infections in Japan","volume":"4","author":"Takahashi","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.jiac.2018.05.010_bib2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrmicro2164","article-title":"Clostridium difficile infection: new developments in epidemiology and pathogenesis","volume":"7","author":"Rupnik","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jiac.2018.05.010_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nature13828","article-title":"Precision microbiome reconstitution restores bile acid-mediated resistance to Clostridium difficile","volume":"517","author":"Buffie","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jiac.2018.05.010_bib4","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3748\/wjg.15.1554","article-title":"Clostridium difficile associated infection, diarrhea and colitis","volume":"15","author":"Hookman","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jiac.2018.05.010_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.anaerobe.2013.10.004","article-title":"Incidence and mortality associated with Clostridium difficile infection at a Japanese tertiary care center","volume":"25","author":"Honda","year":"2014","journal-title":"Anaerobe"},{"key":"10.1016\/j.jiac.2018.05.010_bib6","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s10096-017-3018-4","article-title":"Adherence to clinical practice guidelines for the management of Clostridium difficile infection in Japan: a multicenter retrospective study","volume":"36","author":"Kobayashi","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2018.05.010_bib7","first-page":"191","article-title":"Risk factors for recurrent hospital-acquired Clostridium difficile infection in a Japanese university hospital","volume":"8","author":"Hikone","year":"2015","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.jiac.2018.05.010_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jiac.2017.10.005","article-title":"The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients","volume":"24","author":"Mikamo","year":"2018","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2018.05.010_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jiac.2017.09.002","article-title":"JAID\/JSC guidelines for infection treatment 2015-intestinal infections","volume":"24","author":"Ohnishi","year":"2018","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2018.05.010_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jhin.2015.03.001","article-title":"Highlighting clinical needs in Clostridium difficile infection: the views of European healthcare professionals at the front line","volume":"90","author":"Aguado","year":"2015","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1016\/j.jiac.2018.05.010_bib11","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s15010-015-0810-x","article-title":"Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital","volume":"43","author":"Heimann","year":"2015","journal-title":"Infection"},{"key":"10.1016\/j.jiac.2018.05.010_bib12","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/infdis\/jiv256","article-title":"Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole","volume":"212","author":"Lewis","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jiac.2018.05.010_bib13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/jac\/dkw383","article-title":"Short- and long-term effects of oral vancomycin on the human intestinal microbiota","volume":"72","author":"Isaac","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2018.05.010_bib14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jiac.2018.05.010_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiac.2018.05.010_bib16","series-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard\u2014eighth edition","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.jiac.2018.05.010_bib17","series-title":"Performance standards for antimicrobial susceptibility testing, 24th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2014"},{"key":"10.1016\/j.jiac.2018.05.010_bib18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1586\/eri.11.53","article-title":"Fidaxomicin: first-in-class macrocyclic antibiotic","volume":"9","author":"Mullane","year":"2011","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jiac.2018.05.010_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jac\/dkt347","article-title":"Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure","volume":"69","author":"Chilton","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2018.05.010_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/ajg.2011.398","article-title":"The epidemiology of community-acquired Clostridium difficile infection: a population-based study","volume":"107","author":"Khanna","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jiac.2018.05.010_bib21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40261-015-0291-9","article-title":"Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjects","volume":"35","author":"Oshima","year":"2015","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jiac.2018.05.010_bib22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/JCM.01796-09","article-title":"Multilocus sequence typing of Clostridium difficile","volume":"48","author":"Griffiths","year":"2010","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.jiac.2018.05.010_bib23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40121-018-0186-1","article-title":"The epidemiology of Clostridium difficile infection in Japan: a systematic review","volume":"7","author":"Riley","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2018.05.010_bib24","article-title":"The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011\u20132014","volume":"0","author":"Freeman","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2018.05.010_bib25","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1128\/JCM.02250-16","article-title":"Update on antimicrobial resistance in Clostridium difficile: resistance mechanisms and antimicrobial susceptibility testing","volume":"55","author":"Peng","year":"2017","journal-title":"J\u00a0Clin Microbiol"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X18301570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X18301570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:57:25Z","timestamp":1761159445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X18301570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1341321X18301570"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2018.05.010","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2018.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}